> ## Content Index
> Fetch the complete content index at: https://www.healthdatacon.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# 23andMe’s nonprofit helps Scripps find volunteers for Alzheimer’s prevention research
- URL: https://www.healthdatacon.io/articles/anne-wojcicki-23andme-data-deletions-hlth-2026/
- Published: 2026-11-17T01:10:00.000Z
- Updated: 2026-11-18T06:23:25.000Z
- Description: Anne Wojcicki described how the institute uses opt-in genetic data to invite people to studies and plans to support questions that draw less commercial investment.
- Author: HDM Staff
- Tags: Informatics, Americas, HLTH

The nonprofit 23andMe Research Institute is helping Scripps Research recruit for an Alzheimer’s prevention study by inviting potentially eligible people who have chosen to hear about research opportunities. Anne Wojcicki, the institute’s founder and CEO, described the partnership on Nov. 16 as an example of what she wants the organization to do with its research cohort. The project gives scientists a way to reach people who might qualify for a study and gives those people the opportunity to decide whether to enroll.

CNN medical correspondent Meg Tirrell [moderated the conversation](https://hlth.com/event-recordings/hlth26/sessions/back-from-the-brink-23andmes-reinvention?ref=healthdatacon.io) on the Main Stage in Las Vegas. She asked what people can do with genetic information once they have it, and what the nonprofit might do that the former public company could not. Wojcicki said the institute should make it easier for people to learn about themselves and help researchers pursue questions for which commercial funding may be harder to find. The Scripps partnership shows what that ambition looks like at the point where a scientific question has to become a study people can actually join.

![Anne Wojcicki and Meg Tirrell seated on the HLTH USA main stage.](https://storage.ghost.io/c/91/db/91db0927-dd9a-4578-9944-921da70f6885/content/images/2026/11/hlth-anne-wojcicki-meg-tirrell.jpg)

Anne Wojcicki, left, speaks with CNN medical correspondent Meg Tirrell at HLTH USA in Las Vegas. Photo credit: Health Data Management.

## From a research notification to enrollment

The [Wellderly Brain Study partnership](https://www.23andme.org/media-center/press-releases/23andme-research-institute-and-scripps-research-announce-partnership/?ref=healthdatacon.io) was announced Nov. 11\. Scripps Research, through its Translational Institute, leads the study, and 23andMe is the recruitment partner. The institute says it sends notifications to potentially eligible participants who have opted to hear about research opportunities. People who want to learn more or enroll work with the Scripps study team. Wojcicki said the study would seek people who carry the APOE ε4 variant, which is associated with a higher risk of Alzheimer’s disease.

That division of work is important. A person may match an initial recruitment criterion and still need to answer eligibility questions or decide that the study is too demanding. Being invited does not mean they have enrolled. A recruitment partner can help a study team reach likely volunteers, while the study team remains responsible for enrolling participants and carrying out the research. Keeping those steps distinct also helps explain why a large pool of people eligible to hear about a study tells researchers little on its own about who will ultimately participate.

Scripps plans to compare digitally delivered lifestyle coaching with education alone. The study will look at measures including blood levels of p-tau217, a biomarker associated with Alzheimer’s disease, along with measures of cognition and biological aging. The announcement says the researchers aim to screen and randomize roughly 1,200 people at risk and estimate the trial will run for 14 to 16 months. Those are plans for the study. Whether coaching changes a biomarker, and what that change would mean for a person’s future risk of disease, are questions the partnership announcement leaves open.

The digital design allows people to enroll and contribute data without making each visit to a research center. That may make participation easier for some volunteers. It also makes it important to know who is able to remain in a digitally delivered study and who drops out. Where recruitment starts with a consumer testing cohort, researchers also have to consider how the people who saw the invitation and chose to enroll compare with the people to whom they hope to apply the results.

## More research questions from a nonprofit cohort

![Anne Wojcicki seated on the HLTH USA main stage.](https://storage.ghost.io/c/91/db/91db0927-dd9a-4578-9944-921da70f6885/content/images/2026/11/hlth-anne-wojcicki.jpg)

Anne Wojcicki, founder and CEO of the 23andMe Research Institute, at HLTH USA. Photo credit: Health Data Management.

Wojcicki said the institute has roughly 11 million people who agreed to participate in research. She wants the nonprofit to support commercial as well as noncommercial investigators and to make room for work that has no immediate product attached. She described that as “research for the sake of humanity.” The institute’s [inaugural scientific advisory board](https://www.23andme.org/media-center/press-releases/23andme-research-institute-announces-inaugural-scientific-advisory-board/?ref=healthdatacon.io), announced in October, is intended to advise on scientific strategy. The next test is which studies the organization supports and what researchers can learn from them.

Wojcicki also pointed to the institute’s work on why people respond differently to GLP-1 medicines. A [Nature study](https://pubmed.ncbi.nlm.nih.gov/41951734/?ref=healthdatacon.io) analyzed self-reported weight loss and side effects in 27,885 people who had used those medicines. It found a genetic association with a modest difference in weight loss. That kind of finding can give researchers a reason to investigate variation in response. It does not establish that using genetic information to choose a drug would improve care. The GLP-1 analysis and the Scripps partnership use the cohort in different ways. One asks what patterns exist in data people have contributed. The other uses what is already known to find people who might want to help answer a new question.

## Choice is part of the research design

“I always want to give customers choice,” Wojcicki said. That choice has multiple parts. A customer can choose whether to participate in the institute’s research, whether to hear from the institute about study opportunities and whether to enroll after an invitation. The institute’s [consent policy](https://support.23andme.org/hc/en-us/articles/42965484883607-Research-Participation-and-Consent?ref=healthdatacon.io) says someone can withdraw from its research without losing access to their genetic information. Data already incorporated into a study cannot be pulled back, and the institute says it will exclude a person’s data from studies that start more than 30 days after they opt out.

![Meg Tirrell seated on the HLTH USA main stage.](https://storage.ghost.io/c/91/db/91db0927-dd9a-4578-9944-921da70f6885/content/images/2026/11/hlth-meg-tirrell.jpg)

CNN medical correspondent Meg Tirrell moderated the HLTH USA session. Photo credit: Health Data Management.

Tirrell asked how the institute could earn trust after the old company’s bankruptcy. The nonprofit [acquired the genetic testing and research services businesses](https://www.23andme.org/media-center/press-releases/ttam-research-institute-nonprofit-public-benefit-corporation/?ref=healthdatacon.io) in July 2025\. Wojcicki said she expected the organization to be judged by how it conducts studies, chooses partners and communicates with customers. The details of an invitation offer one way to see how that works. A potential volunteer needs to know why they were contacted, who is running the study and what agreeing to enroll would involve.

Another issue is how the institute will choose studies when several investigators want to reach the same volunteers. A scientific advisory board can help set priorities. The discussion did not specify which projects will have access or how often participants can expect to hear from researchers.

The Scripps study gives the nonprofit a concrete opportunity to show what its research cohort can contribute. It can help scientists reach people who might otherwise never encounter the study. Enrollment and follow-up belong to the study team, and the results will determine what can be said about coaching and the measures the researchers chose. For Wojcicki’s broader ambitions, the partnership will also show how well the institute can connect people with research while preserving their ability to decide how they take part.